WordNet

travel or traverse (a distance); "This car does 150 miles per hour"; "We did 6 miles on our hike every day"
the syllable naming the first (tonic) note of any major scale in solmization (同)doh, ut
proceed or get along; "How is she doing in her new job?"; "How are you making out in graduate school?"; "Hes come a long way" (同)fare, make_out, come, get along
create or design, often in a certain way; "Do my room in blue"; "I did this piece in wood to express my love for the forest" (同)make
carry on or function; "We could do with a little more help around here" (同)manage
get (something) done; "I did my job" (同)perform
treat with an agent; add (an agent) to; "The ray dosed the paint"
the quantity of an active agent (substance or radiation) taken in or absorbed at any one time (同)dosage
a measured portion of medicine taken at any one time (同)dosage
a state of surviving; remaining alive (同)endurance
a natural process resulting in the evolution of organisms best adapted to the environment (同)survival of the fittest, natural_selection, selection
something that survives
treated with some kind of application; "a mustache dosed with bear grease"

PrepTutorEJDIC

《疑問文・否定文を作る》 / 《否定命令文を作る》 / 《助動詞とbe動詞のどちらも含まない文に用いて付加疑問を作る》 / 《強意語として》 / 《文》《助動詞とbe動詞のどちらも含まない文に用いて倒置文を作る》 / 《あいづちを打つ場合に》 / 《先行する動詞またはそれを含む述部の代用》 / 《so,nor,neitherで始まる簡略文で》 / …‘を'『する』,行う,果たす / 《通例have done,時にbe doneの形で》…‘を'『終える』,済ませる / …‘を'作る,作り出す / …‘を'『処理する』,整える,片付ける / 〈学課〉‘を'『勉強する』,専攻する / 〈利益・害など〉‘を'与える,もたらす / 〈人〉‘に'『役立つ』,用が足りる(serve) / …の速度で進む,距離を行く / …‘を'見物する / 〈劇〉‘を'上演する;…‘の'役を演じる / …の役目(仕事)をする / 《おもに英》…‘を'だます,かつぐ / 《話》…をへとへとにさせる / 『する』;活動する / 《通例have done,時にbe doneの形で》(…を)『終える』,済ます《+『with』+『名』》 / 〈事が〉『運ぶ』;〈人が〉暮らしていく,健康である / 〈物が〉(…に)『間に合う』,十分である;〈人が〉(…に)役に立つ,向く《+『for』+『名』》 / 《複数形で》すべきこと / 〈C〉《おもに英》大宴会,大パーティー / 〈C〉《英話》詐欺,ぺてん
ド(全音階の第1音)
(おもに飲み薬1回分の)『服用量』 / (痛いこと・いやなことの)1回分,一定量 / (人などが受ける放射線の)線量 / 性病 / (…を)…‘に'投薬する,服用させる《+『名』+『with』+『名』》
〈U〉(…が)生き残ること,(…の)生存,残存《+of+名》 / 〈C〉生存者,残存者;残存物,遺物

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 小児における痙攣およびてんかん症候群の治療の概要 overview of the treatment of seizures and epileptic syndromes in children
2. 小細胞肺癌患者に対する予防的全脳照射 prophylactic cranial irradiation for patients with small cell lung cancer
3. 成人における放射線障害の生物学および臨床的特徴 biology and clinical features of radiation injury in adults
4. 双胎妊娠：陣痛および分娩 twin pregnancy labor and delivery
5. 横位の胎児のマネージメント management of the fetus in transverse lie

English Journal

Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant.

Gupta A1, Punatar S1, Gawande J1, Mathew L1, Bagal B1, Kannan S2, Khattry N1.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion.Indian J Hematol Blood Transfus.2015 Dec;31(4):404-12. doi: 10.1007/s12288-014-0499-5. Epub 2015 Jan 7.
We sought to determine risk factors, pattern and outcome of acute graft versus host disease (aGVHD) in seventy-seven acute leukemia patients who underwent allogeneic stem cell transplant at our centre from January 2008 to March 2013. GVHD prophylaxis with cyclosporine-methotrexate or cyclosporine-my
PMID 26306063

Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.

Geller BJ1, Giugliano RP2, Braunwald E2, Murphy SA2, Hanyok JJ3, Jin J3, Mercuri M3, Antman EM2, Ruff CT4.
American heart journal.Am Heart J.2015 Oct;170(4):669-74. doi: 10.1016/j.ahj.2015.06.020. Epub 2015 Jul 2.
BACKGROUND: Atrial fibrillation (AF) is a major risk factor for stroke and systemic embolism. Trials comparing warfarin with non-vitamin K oral anticoagulants (NOACs) have demonstrated that, when compared with warfarin, the NOACs are at least as effective in preventing stroke, although detailed anal
PMID 26386790

Occult Dermal Lymphatic Involvement Is Frequent in Primary Cutaneous Anaplastic Large Cell Lymphoma.

Gratzinger D1, Million L, Kim YH.
The American Journal of dermatopathology.Am J Dermatopathol.2015 Oct;37(10):767-70. doi: 10.1097/DAD.0000000000000377.
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is an indolent T-cell lymphoproliferative disorder managed with low-dose radiation therapy, surgery, and/or mild chemotherapy; patients with extensive limb disease (ELD) have a more aggressive clinical course. We have previously demonstrated
PMID 26381026

Japanese Journal

Rituximab投与ABO血液型不適合生体肝移植における安全性と有効性に関する後方視的調査研究

江川裕人,尾形哲,山本雅一,高原武志,若林剛,藤山泰二,高田泰次,保田裕子,八木孝仁,岡島英明,海道利実,上本伸二,伊藤孝司,吉村了勇,吉住朋晴,調憲,前原喜彦,阪本靖介,猪股裕紀洋,篠田昌宏,板野理,北川雄光,川岸直樹,石山宏平,井手健太郎,大段秀樹,水野修吾,伊佐地秀司,浅岡忠史,永野浩昭,梅下浩司,日髙匡章,江口晋,小倉靖弘
移植 50(1), 062-077, 2015
… 【Objective】To estimate a standard dosage of rituximab prophylaxis for ABO incompatible living donor liver transplantation (ABO-I LDLT), we retrospectively investigated rituximab dosage, efficacy and safety in 37 patients including 4 children undergoing ABO-I LDLT with rituximab prophylaxis in 15 centers in 2013.【Methods】We analyzed the data collected by questionnaire that were sent to registered surgeons or hepatologists of the Japanese Liver Transplantation Society.【Results】Doses of rituximab in adult patients were 500 mg/body in 16 cases …
NAID 130005064485

篩骨洞原発混合型小細胞癌の1例

岡崎雅,白倉聡,畑中章生,得丸貴夫,藤川太郎,山田雅人,別府武
頭頸部癌 40(4), 422-425, 2014
混合型小細胞癌は小細胞癌と扁平上皮癌あるいは腺癌などが混在する腫瘍の総称である。いわゆる小細胞癌と同様に肺に好発することが知られており，高率に遠隔転移を生じることから予後不良と考えられている。頭頸部領域では腺癌との混合型の報告は認めない。当センターで治療を行い長期生存が得られている篩骨洞原発の混合型小細胞癌（小細胞癌と腺癌の混合型）について報告する。症例は53歳男性，頸部腫瘤と鼻出血を主訴に当科受 …
NAID 130004940794

ORI2 Inhibits Coxsackievirus Replication and Myocardial Inflammation in Experimental Murine Myocarditis

Lim Byung-Kwan,Kim Jin Hee
Biological and Pharmaceutical Bulletin 37
… Antiviral compounds were screened by HeLa cell survival assay. … ORI2 significantly improved HeLa cell survival in a dose-dependent manner. … ORI2 treatment significantly improved early survival in the treated mice compared to untreated mice (85% vs. 50%, respectively). …
NAID 130004693797